Loading
Life sciences · Journal article
Obm Transplantation · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
After liver transplantation, colorectal cancer (CRC) recurrence is a serious clinical issue. This underscores the need to understand the molecular and immunometabolic axes that promote tumor development and transplant fragility. This research combines compound-gene network analysis, immune cell deconvolution, and transcriptome profiling to find important genes and pathways that connect post-transplant immune modulation and CRC development. ADH1B, ALB, and ZG16 are consistently altered in primary colorectal malignancies, metastatic liver lesions, and transplanted hepatic tissue. These genes are involved in ethanol and retinol metabolism, systemic inflammation, immune cell infiltration, and preservation of the mucosal barrier. Our research shows that these genes are at the center of a common immunometabolic axis that lets the body change its metabolism and evade the immune system. Curcumin, beta-carotene, resveratrol, and D-mannitol are some of the bioactive dietary compounds that we find target these genes and related pathways. These could improve clinical outcomes in liver transplantation and colorectal cancer by changing how the immune system works. In addition to recommending ADH1B and ALB as potential biomarkers for recurrence monitoring and therapeutic targeting, this work offers a unified model of tumor-host-graft interactions. These findings lay the groundwork for future investigations that combine single-cell and spatial analysis to better understand gene function and direct precision therapies in transplant medicine and cancer, and are particularly relevant to patients undergoing liver transplantation for unresectable colorectal liver metastases (CRLM).